Mission Statement
Empowering our clients and families with knowledge, through quality comprehensive programs and services.
Empowering our clients and families with knowledge, through quality comprehensive programs and services.
exciting news - gene therapies have been approved!
The Sickle Cell Disease Association of America, Inc. (SCDAA) reported, "On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy from CRISPR/Vertex and Lyfgenia from bluebird bio." SCDAA went on to explain, "these are the first treatments of their kind available to individuals with SCD in the United States. The approval of these potentially curative therapies marks a major advance in the treatment of sickle cell disease; however, there are valid concerns about accessibility and the potential for adverse effects. Click the buttons below to learn more about these approvals."
Click the link below to read more about these landmark approvals:
SCDAA Statement on Gene Therapy Approval
Gene Therapy: What You Need To Know
Click the link below to read more about these landmark approvals:
SCDAA Statement on Gene Therapy Approval
Gene Therapy: What You Need To Know
The purchase of a Sickle Cell Awareness specialty license plate supports this association. Funds will come back to our organization, and will be used to support research, clinical care, and community services relevant to sickle cell disease.
The SCDAA – Mobile Chapter offers free screening for sickle cell disease and trait. If you are interested in being tested, please call 251-432-0301 and schedule and appointment.
